Pak Fah Yeow International Limited (0239.HK)
HKD 2.44
(0.41%)
HKD 2.44
(0.41%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 142.28 Million HKD | 22.75% |
| 2022 | 115.91 Million HKD | -10.86% |
| 2021 | 130.02 Million HKD | 6.4% |
| 2020 | 122.2 Million HKD | -19.46% |
| 2019 | 151.73 Million HKD | -4.05% |
| 2018 | 158.13 Million HKD | 5.24% |
| 2017 | 150.26 Million HKD | 15.28% |
| 2016 | 130.35 Million HKD | -11.86% |
| 2015 | 147.89 Million HKD | -1.63% |
| 2014 | 150.35 Million HKD | -9.31% |
| 2013 | 165.78 Million HKD | -3.72% |
| 2012 | 172.18 Million HKD | 31.38% |
| 2011 | 131.05 Million HKD | 2.5% |
| 2010 | 127.86 Million HKD | -3.55% |
| 2009 | 132.58 Million HKD | -9.61% |
| 2008 | 146.66 Million HKD | 16.73% |
| 2007 | 125.64 Million HKD | 3.95% |
| 2006 | 120.87 Million HKD | 9.37% |
| 2005 | 110.51 Million HKD | -12.18% |
| 2004 | 125.83 Million HKD | 34.53% |
| 2003 | 93.53 Million HKD | -6.48% |
| 2002 | 100.02 Million HKD | 12.97% |
| 2001 | 88.54 Million HKD | 33.65% |
| 2000 | 66.25 Million HKD | 0.84% |
| 1999 | 65.69 Million HKD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 183.65 Million HKD | 0.0% |
| 2023 FY | 142.28 Million HKD | 22.75% |
| 2023 Q4 | 142.28 Million HKD | 0.0% |
| 2023 Q2 | 155.62 Million HKD | 0.0% |
| 2022 Q4 | 115.91 Million HKD | 0.0% |
| 2022 Q2 | 145.62 Million HKD | 0.0% |
| 2022 FY | 115.91 Million HKD | -10.86% |
| 2021 Q2 | 146.06 Million HKD | 0.0% |
| 2021 Q4 | 130.02 Million HKD | 0.0% |
| 2021 FY | 130.02 Million HKD | 6.4% |
| 2020 FY | 122.2 Million HKD | -19.46% |
| 2020 Q2 | 143.69 Million HKD | 0.0% |
| 2020 Q4 | 122.2 Million HKD | 0.0% |
| 2019 FY | 151.73 Million HKD | -4.05% |
| 2019 Q4 | 151.73 Million HKD | 0.0% |
| 2019 Q2 | 169.77 Million HKD | 0.0% |
| 2018 FY | 158.13 Million HKD | 5.24% |
| 2018 Q2 | 177.26 Million HKD | 0.0% |
| 2018 Q4 | 158.13 Million HKD | 0.0% |
| 2017 Q4 | 150.26 Million HKD | 0.0% |
| 2017 Q2 | 165.13 Million HKD | 0.0% |
| 2017 FY | 150.26 Million HKD | 15.28% |
| 2016 Q2 | 164.71 Million HKD | 0.0% |
| 2016 Q4 | 130.35 Million HKD | 0.0% |
| 2016 FY | 130.35 Million HKD | -11.86% |
| 2015 FY | 147.89 Million HKD | -1.63% |
| 2015 Q4 | 147.89 Million HKD | 0.0% |
| 2015 Q2 | 189 Million HKD | 0.0% |
| 2014 FY | 150.35 Million HKD | -9.31% |
| 2014 Q4 | 150.35 Million HKD | 0.0% |
| 2014 Q2 | 194.35 Million HKD | 0.0% |
| 2013 Q4 | 165.78 Million HKD | 0.0% |
| 2013 FY | 165.78 Million HKD | -3.72% |
| 2013 Q2 | 190.94 Million HKD | 0.0% |
| 2012 Q4 | 172.18 Million HKD | 0.0% |
| 2012 Q2 | 161.12 Million HKD | 0.0% |
| 2012 FY | 172.18 Million HKD | 31.38% |
| 2011 Q2 | 159.19 Million HKD | 0.0% |
| 2011 FY | 131.05 Million HKD | 2.5% |
| 2011 Q4 | 131.05 Million HKD | 0.0% |
| 2010 Q2 | 162.47 Million HKD | 0.0% |
| 2010 Q4 | 127.86 Million HKD | 0.0% |
| 2010 FY | 127.86 Million HKD | -3.55% |
| 2009 Q4 | 132.58 Million HKD | 0.0% |
| 2009 FY | 132.58 Million HKD | -9.61% |
| 2008 FY | 146.66 Million HKD | 16.73% |
| 2007 FY | 125.64 Million HKD | 3.95% |
| 2006 FY | 120.87 Million HKD | 9.37% |
| 2005 FY | 110.51 Million HKD | -12.18% |
| 2004 FY | 125.83 Million HKD | 34.53% |
| 2003 FY | 93.53 Million HKD | -6.48% |
| 2002 FY | 100.02 Million HKD | 12.97% |
| 2001 FY | 88.54 Million HKD | 33.65% |
| 2000 FY | 66.25 Million HKD | 0.84% |
| 1999 FY | 65.69 Million HKD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 98.036% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | 16.505% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | 79.951% |
| Qianhai Health Holdings Limited | 94 Million HKD | -51.359% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 84.702% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 84.257% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | 78.617% |
| PuraPharm Corporation Limited | 689.65 Million HKD | 79.369% |
| SSY Group Limited | 4.49 Billion HKD | 96.834% |
| JBM (Healthcare) Limited | 366.75 Million HKD | 61.205% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 86.953% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.916% |